Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.

Andrea DuminucoAntonella NardoAlessandra OrofinoGiuliana GiuntaConcetta ConticelloVittorio Del FabroAnnalisa ChiarenzaMarina S ParisiAmalia FigueraSalvatore LeottaGiuseppe MiloneAlessandra CupriDaniela CambriaFrancesco Di RaimondoAlessandra RomanoGiuseppe A Palumbo

Published in: Cancer (2023)

Prophylaxis treatment seems to be a valid and safe strategy, although not preventing breakthrough infection, but the severe complications associated with the infection and the possible delays in administering lifesaving therapies from long positivity.

Keyphrases

sars cov
early onset
risk factors
respiratory syndrome coronavirus
combination therapy